The development of innovative medicines has been impacting an ever-growing number of patients in western countries over the last ten years.
However, territories such as the Middle East, Central Europe or even Africa, only benefit from these advances much later on.
Indeed, an innovative compound launched in Europe or the United States, will only appear in the Middle East 5 to 7 years after becoming available in Europe. There are various reasons for this:
– Priority being given to the country of origin
– Geographic distance or cultural remoteness
Awareness of how to gain access to innovative treatments has also grown in these markets, at the level of supervisory authorities as well as practising doctors and patients - patients who benefit from information that moves faster than ever before.
Cytis AG has set itself the ambitious mission of providing for the needs of such patients and their families, while at the same time contributing to the geographic expansion of innovative businesses, whether this is in the biopharmaceutical, medical equipment or diagnostics field.